CN111148735B - 含氮杂芳基化合物及其药物用途 - Google Patents

含氮杂芳基化合物及其药物用途 Download PDF

Info

Publication number
CN111148735B
CN111148735B CN201880064738.0A CN201880064738A CN111148735B CN 111148735 B CN111148735 B CN 111148735B CN 201880064738 A CN201880064738 A CN 201880064738A CN 111148735 B CN111148735 B CN 111148735B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880064738.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111148735A (zh
Inventor
长森弘将
西丸达也
高木正树
三谷育生
中川祐一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CN111148735A publication Critical patent/CN111148735A/zh
Application granted granted Critical
Publication of CN111148735B publication Critical patent/CN111148735B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880064738.0A 2017-10-04 2018-10-03 含氮杂芳基化合物及其药物用途 Active CN111148735B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-194005 2017-10-04
JP2017194005 2017-10-04
PCT/JP2018/037007 WO2019069973A1 (ja) 2017-10-04 2018-10-03 含窒素ヘテロアリール化合物およびその医薬用途

Publications (2)

Publication Number Publication Date
CN111148735A CN111148735A (zh) 2020-05-12
CN111148735B true CN111148735B (zh) 2023-08-08

Family

ID=65994698

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880064738.0A Active CN111148735B (zh) 2017-10-04 2018-10-03 含氮杂芳基化合物及其药物用途

Country Status (19)

Country Link
US (1) US10752596B2 (OSRAM)
EP (1) EP3693358B1 (OSRAM)
JP (1) JP7125882B2 (OSRAM)
KR (1) KR20200064101A (OSRAM)
CN (1) CN111148735B (OSRAM)
AR (1) AR113270A1 (OSRAM)
AU (1) AU2018345221A1 (OSRAM)
BR (1) BR112020004857A2 (OSRAM)
CA (1) CA3074989A1 (OSRAM)
CL (1) CL2020000898A1 (OSRAM)
CO (1) CO2020003977A2 (OSRAM)
IL (1) IL273573A (OSRAM)
MX (1) MX2020003816A (OSRAM)
PE (1) PE20200846A1 (OSRAM)
PH (1) PH12020550403A1 (OSRAM)
RU (1) RU2020115045A (OSRAM)
SG (1) SG11202003005PA (OSRAM)
TW (1) TW201922706A (OSRAM)
WO (1) WO2019069973A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110156698B (zh) * 2019-06-06 2020-10-13 沈阳海诺威医药科技有限公司 2-苯基-1，6-二氢嘧啶-5-甲酸衍生物的制备方法和用途
CN113181206B (zh) * 2021-04-30 2023-07-14 青岛大学 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用
CA3244306A1 (en) * 2022-01-07 2023-07-13 Horizon Therapeutics Ireland Dac GLUT9 HETEROCYCLIC INHIBITORS FOR THE TREATMENT OF A DISEASE
CN114805192B (zh) * 2022-03-30 2023-05-23 华南理工大学 一种含2-羟基苯甲酸的三环类xor/urat1双重抑制剂及其制备方法与应用
WO2024167952A1 (en) * 2023-02-08 2024-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oxidatively cleavable organophosphate drugs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003484A1 (en) * 1996-07-18 1998-01-29 Merck Frosst Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO2008126901A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
JP2009016193A (ja) * 2007-07-05 2009-01-22 Daihen Corp 電気機器用樹脂ブッシング
WO2011119866A1 (en) * 2010-03-24 2011-09-29 Ohio University Compositions and methods for glucose transport inhibition
CN104306363A (zh) * 2014-10-31 2015-01-28 南京葆赫生物技术有限公司 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用
EP3181557A1 (en) * 2014-08-13 2017-06-21 Shanghai Shaletech Technology Co., Ltd. Carboxylic acid compound, method for preparation thereof, and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP1070714B1 (en) * 1998-04-10 2004-08-04 Japan Tobacco Inc. Amidine compounds
JP2007501801A (ja) * 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
JP2007176933A (ja) 2005-11-29 2007-07-12 Tanabe Seiyaku Co Ltd 医薬組成物
JP5162827B2 (ja) 2005-12-27 2013-03-13 ぺんてる株式会社 鉛筆芯の製造方法
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003484A1 (en) * 1996-07-18 1998-01-29 Merck Frosst Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO2008126901A1 (ja) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
JP2009016193A (ja) * 2007-07-05 2009-01-22 Daihen Corp 電気機器用樹脂ブッシング
WO2011119866A1 (en) * 2010-03-24 2011-09-29 Ohio University Compositions and methods for glucose transport inhibition
EP3181557A1 (en) * 2014-08-13 2017-06-21 Shanghai Shaletech Technology Co., Ltd. Carboxylic acid compound, method for preparation thereof, and use thereof
CN104306363A (zh) * 2014-10-31 2015-01-28 南京葆赫生物技术有限公司 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1";WU, F. 等;《 Journal of Medicinal Chemistry》;20151210;第59卷(第1期);第253-263页 *

Also Published As

Publication number Publication date
EP3693358A4 (en) 2021-06-02
EP3693358A1 (en) 2020-08-12
TW201922706A (zh) 2019-06-16
IL273573A (en) 2020-05-31
RU2020115045A (ru) 2021-11-08
EP3693358B1 (en) 2023-02-22
BR112020004857A2 (pt) 2020-09-15
CL2020000898A1 (es) 2020-08-14
WO2019069973A1 (ja) 2019-04-11
AU2018345221A1 (en) 2020-05-07
SG11202003005PA (en) 2020-04-29
PE20200846A1 (es) 2020-08-18
US10752596B2 (en) 2020-08-25
JP2019065009A (ja) 2019-04-25
US20190152926A1 (en) 2019-05-23
JP7125882B2 (ja) 2022-08-25
CN111148735A (zh) 2020-05-12
AR113270A1 (es) 2020-03-11
CO2020003977A2 (es) 2020-04-24
CA3074989A1 (en) 2019-04-11
MX2020003816A (es) 2020-08-13
PH12020550403A1 (en) 2021-02-15
KR20200064101A (ko) 2020-06-05

Similar Documents

Publication Publication Date Title
CN111148735B (zh) 含氮杂芳基化合物及其药物用途
JP5715713B2 (ja) 可溶性グアニル酸シクラーゼ活性化因子
TWI585088B (zh) 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
KR100810468B1 (ko) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
US10195186B2 (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
TWI654172B (zh) 環烷基甲酸類衍生物、其製備方法及其在醫藥上的應用
TWI691475B (zh) Ｕｒａｔ１抑制劑
TWI435875B (zh) 含氮芳香族雜環化合物
KR101866706B1 (ko) 1-알킬-6-옥소-1,6-디하이드로피리딘-3-일 화합물과 sgrm 조절인자로서의 용도
JP2020502111A (ja) 新規フェニルプロピオン酸誘導体及びその用途
EP2492266B1 (en) 5-hydroxypyrimidine-4-carboxamide derivative
JP7446460B2 (ja) 新規ｅｐ４拮抗薬の合成及びその癌及び炎症における使用
Yang et al. Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3, 5-dimethylisoxazole
JP2025509404A (ja) Ｐｒｍｔ５のｍｔａ協働阻害剤としての４－（アミノメチル）－６－（１－メチル－１ｈ－ピラゾール－４－イル）イソキノリン－１（２ｈ）－オン誘導体
ES2965041T3 (es) Composiciones para el tratamiento de la fibrosis pulmonar
TW201542525A (zh) 肺疾患的治療及／或預防用的醫藥組成物
JP4749335B2 (ja) イミダゾピリジン化合物
HK40027595A (en) Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
EP4488271A1 (en) Indazole compound and pharmaceutical use thereof
HK40123212A (en) Indazole compound and pharmaceutical use thereof
WO2022037601A1 (zh) 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
HK40081475A (en) Synthesis of novel ep4 antagonist and use in cancers and inflammations
TW201617076A (zh) 取代聯芳基化合物及其他醫藥之組合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant